



144448 11

PATENT
Attorney Docket No. A-67689-3/RFT/RMS/RMK
Dorsey File No. 469443-11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HORWITZ, David A.

Serial No.: 09/653,924

Filing Date: September 1, 2000

For: *Use of Cytokines, Cells, and Mitogens
to Inhibit Graft Versus Host Disease*

Examiner: HADDAD, M. M.

Art Unit: 1644

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

Dated: March 13, 2003

Signed: Marjorie Jost
Marjorie Jost

RECEIVED
MAY 26 2003
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the reference cited on the accompanying substitute for form PTO-1449. Copies of the references are enclosed herewith.

None of the foregoing references is believed to disclose the invention as claimed.

Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application.

Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

1106628_1.DOC

03/21/2003 MMKONEN 00000072 09653924
01 FC:1805 180.00 0P


Serial No.: 09/653,924
Filing Date: September 1, 2000

Pursuant to 37 C.F.R. §1.97(c), enclosed is a check in the amount of \$180.00 as set forth in 37 C.F.R. §1.17(p). While no further fee is believed to be due, if this belief is in error, the Commissioner is authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order No. 469443-11 (A-67689-3/RFT/RMS/RMK)).

Please direct any calls in connection with this application to the undersigned at (415) 781-1989.

Respectfully submitted,

DORSEY & WHITNEY LLP

BY: 

Renee M. Kossak, Reg. No. 47,717 for
Robin M. Silva, Reg. No. 38,304
Filed under 37 C.F.R. § 1.34(a)

Dated: 3/12/03
Customer Number: 32940
Dorsey & Whitney LLP
Intellectual Property Department
Four Embarcadero Center, Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 781-1989
Facsimile: (415) 398-3249



Substitute PTO/SB/8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO
(Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Completer if Known

Application Number	09/653,924
Filing Date	September 1, 2000
First Named Inventor	HORWITZ, David A.
Group Art Unit	1644
Examiner Name	HADDAD, Maher M.

Sheet

1

of

1

Attorney Docket Number

A-67689-3/RFT/RMS/RMK (469443-11)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A1					
A2					
A3					
A4					
A5					
A6					
A7					
A8					
A9					
A10					
A11					

RECEIVED
MAR 26 2003
TECH CENTER 1600/290C

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
B1						
B2						
B3						
B4						
B5						
B6						

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
C1	HEITGER A, et al.	"Essential role of the thymus to reconstitute naive (CD45RA+) T-helper cells after human allogeneic bone marrow transplantation." Blood. 1997 Jul 15;90(2):850-7.	
C2	CHEN W, et al.	"T cells specific for a polymorphic segment of CD45 induce graft-versus-host disease with predominant pulmonary vasculitis." J Immunol. 1998 Jul 15;161(2):909-18.	
C3	EARLY E, and Reen DJ.	"Rapid conversion of naive to effector T cell function counteracts diminished primary human newborn T cell responses." Clin Exp Immunol. 1999 Jun;116(3):527-33. (Abstract)	
C4	GARDERET L, et al.	"Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations." Transplantation. 1999 Jan 15;67(1):124-30.	
C5			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1106579_1.DOC